

**PRESCRIPTION DRUGS SETTLEMENT 2016 MARCH, 24TH**

HOLKIRA PAK		PATIENTS GENOTYPE 1 Year 2	HARVONI		
12 weeks	24 weeks		8 weeks	12 weeks	24 weeks
		Genotype 1a, Fibrosis 3 score and F2, F1 plus one poor prognosis factor***, naive patient ( never treated before)			
		Genotype 1a Fibrosis 3 score and F2, F1 plus one poor prognosis factor, failure with INF+RBV*			
		Genotype 1a, Fibrosis 3 score and F2, F1 plus one poor prognosis factor, failure with INF+RBV+IP**			
		Genotype 1b, Fibrosis 3 score and F2, F1 plus one poor prognosis factor, naive patient ( never treated before)			
		Genotype 1b, Fibrosis 3 score and F2, F1 plus one poor prognosis factor, failure with INF+RBV			
		Genotype 1b, Fibrosis 3 score and F2, F1 plus one poor prognosis factor, failure with INF+RBV+IP*			
		Genotype 1a, Fibrosis 4 score , naive patient ( never treated before)			
		Genotype 1a, Fibrosis 4 score, relapser or partial responder IFN+RBV*			
		Genotype 1a, Fibrosis 4 score, null responder IFN+RBV*			
		Genotype 1a, Fibrosis 4 score, failure with IFN+RBV+IP**			
		Genotype 1b, Fibrosis 4 score, naive patient ( never treated before)			
		Genotype 1b, Fibrosis 4 score, failure with IFN+RBV*			
		Genotype 1a, Fibrosis 4 score, failure with IFN+RBV+IP**			
		Decompensated cirrhosis			
		Waiting for a transplant			
		Post transplant			
		* Interferon + ribavirine			
		** Interferon + ribavirine + protease inhibitor			
		Monotherapy			
		If viral load is under 2,2millions UI/ml (Abbott's marker) or			
		Viral load under 6 millions UI/ml (Roche's marker)			
		With ribavirine			
		If contre-indication or ribavirine intolerance			

**\*\*\* Poor prognosis factor**

- Serious extra-hepatic manifestations (cryoglobulinemia type 2 or 3 with organ damage, vasculitis, B-cell non-Hodgkin's lymphoma, nephropathy)
- Co-Infection (HIV, HBV)
- Another liver disease (non-alcoholic steatohepatitis),
- Type 2 diabetes
- Late-stage cutaneous porphyria